BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BC Extra | Sep 6, 2019
Company News

Taiwan’s JHL to terminate biosimilars programs in Genentech trade secret settlement

JHL Biotech and Genentech have settled a civil suit involving allegations that the Taiwanese start-up stole the Roche unit’s trade secrets. Under terms of the settlement, JHL Biotech Inc. (Zhubei, Taiwan) has agreed to “abandon...
BC Extra | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to...
BioCentury | Aug 16, 2019
Product Development

China’s biosimilars in fast lane

Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade. On February 22, 2019, China’s National...
BC Extra | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

Amgen, Allergan launch pair of biosimilars  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) launched Mvasi bevacizumab-awwb and Kanjinti trastuzumab-anns in the U.S.; they are the first biosimilars of Avastin bevacizumab and Herceptin trastuzumab available in...
BC Extra | May 10, 2019
Company News

May 10 Company Quick Takes: Red flags for Daiichi ahead of ODAC; plus JHL/Genentech, J&J, Gilead

FDA reviewers raise concerns about Daiichi’s quizartinib, pexidartinib  Despite both pexidartinib and quizartinib meeting the primary endpoints in their pivotal trials, FDA reviewers raised concerns about each agent from Daiichi Sankyo Co. Ltd. (Tokyo:4568) in...
BC Extra | Mar 6, 2019
Company News

Judge grants Genentech some relief as JHL trade secret case moves forward

A federal judge ruled in Genentech's favor on multiple issues in its civil suit against Taiwanese company JHL Biotech, but declined to halt JHL's biosimilars development. Judge William Alsup's order was unsealed late Tuesday, following...
BC Week In Review | Feb 28, 2019
Clinical News

China approves first biosimilar, Shanghai Henlius’ HLX01

China's National Medical Products Administration (NMPA) approved the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China). The chimeric mAb against CD20 was approved in China for the same indications as...
BC Extra | Feb 25, 2019
Company News

China approves first biosimilar, Shanghai Henlius’ HLX01

China's National Medical Products Administration (NMPA) approved last Friday the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China). The chimeric mAb against CD20 was approved in China for the same...
Items per page:
1 - 10 of 88